Abbott’s $23 billion acquisition of Exact Sciences positions the company to become a major player in cancer diagnostics. Experts think the deal makes strategic sense, as it offers higher margins and a broader commercial scale — but questions remain about long-term growth amid rising competition and the challenges of integrating a patient-focused, tech-heavy business.
The post Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble? appeared first on MedCity News.
